Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $90.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: 4121.12%
• EPS Growth: 83.30%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 87,405,310
• 10 Day Avg. Volume: 1,954,645
• 30 Day Avg. Volume: 1,333,579
• PEG Ratio: 0.02
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 12.06
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: -0.49
• Enterprise Value/Revenue: -0.39
• Enterprise Value/Gross Profit: -0.42
• Enterprise Value/Ebitda: 3.15
• 1Y Price Target: $5.00
• Price Target Upside: 362.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $0.91 ▼(-16.20% Downside)

Century Therapeutics' stock score is driven by strong technical momentum and positive corporate developments. However, financial performance and valuation remain weak due to ongoing losses and negative cash flow.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful product development and market acceptance, enhancing long-term business prospects and financial stability.

Pipeline Advancements

Advancements in cell therapy pipeline demonstrate strategic focus on innovation, potentially leading to breakthrough treatments and market leadership.

Board Expansion

Expanding the board with experienced members strengthens governance and strategic oversight, supporting long-term growth and operational execution.

Negative Factors

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and can limit the company's ability to invest in growth or weather financial downturns.

Net Loss

Ongoing net losses highlight challenges in achieving profitability, which may pressure financial resources and delay strategic initiatives.

Debt Increase

Rising debt levels, though currently manageable, could increase financial risk and constrain future borrowing capacity if not controlled.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Century Therapeutics generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on future sales of developed therapies. Additionally, the company may receive funding from grants and investments to support its research and development efforts. By focusing on advancing its proprietary iPSC technology, Century aims to establish a strong pipeline of therapies that can be licensed or commercialized, contributing to its overall revenue growth.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics shows significant revenue growth but continues to operate at a net loss with negative EBIT and EBITDA margins. The balance sheet is strong with a high equity ratio and healthy cash reserves, but cash flow is negative, indicating operational inefficiencies.

Income Statement

Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.

Balance Sheet

The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.

Cash Flow

Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	113.34M	6.59M	2.23M	5.20M	0.00	0.00
Gross Profit	107.01M	6.59M	2.23M	5.20M	-4.58M	-1.75M
EBITDA	-14.21M	-111.47M	-121.21M	-121.20M	-89.92M	-51.44M
Net Income	-26.48M	-126.57M	-136.67M	-130.93M	-95.82M	-53.58M
Balance Sheet
Total Assets	244.72M	353.22M	360.69M	486.54M	437.38M	106.78M
Cash, Cash Equivalents and Short-Term Investments	132.75M	189.29M	172.74M	315.50M	222.88M	75.75M
Total Debt	44.96M	53.83M	48.17M	49.41M	25.12M	21.55M
Total Liabilities	68.37M	191.85M	175.94M	183.81M	41.14M	213.19M
Stockholders Equity	176.35M	161.36M	184.75M	302.74M	396.24M	-106.41M
Cash Flow
Free Cash Flow	-112.69M	-110.29M	-102.08M	-16.55M	-133.97M	-51.09M
Operating Cash Flow	-112.02M	-110.14M	-88.35M	14.05M	-89.00M	-41.27M
Investing Cash Flow	115.75M	47.48M	61.13M	-13.13M	-298.34M	-22.76M
Financing Cash Flow	-482.00K	74.56M	-9.72M	27.16M	417.77M	47.69M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 1.08 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.60, and above the 200-day MA of 0.56, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 85.39 is Negative, neither overbought nor oversold. The STOCH value of 94.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IPSC	51 Neutral	$90.90M	-3.49	-14.23%	―	4121.12%	83.30%
LTRN	45 Neutral	$37.36M	-1.99	-104.58%	―	―	1.18%
ATNM	41 Neutral	$49.60M	-1.37	-133.09%	―	11.11%	20.65%
TPST	39 Underperform	$15.18M	-0.30	-405.03%	―	―	49.43%
CALC	39 Underperform	$89.48M	-3.88	-526.36%	―	―	-2.46%
BTAI	37 Underperform	$37.40M	-0.17	―	―	-66.96%	71.83%

Century Therapeutics Corporate Events

Century Therapeutics Updates on Cell Therapy Advancements

On December 12, 2025, Century Therapeutics updated its slide presentation to reflect advancements in its cell therapy pipeline, which will be used in investor meetings. The company is progressing with its Allo-Evasion technology, with key programs like CNTY-101 in Phase 1/2 trials for autoimmune diseases and CNTY-813 in preclinical development for Type 1 Diabetes. The announcement highlights the company’s strategic focus on executing high-impact programs and extending its cash runway beyond key clinical milestones anticipated in late 2027.

Century Therapeutics Expands Board with New Appointments

On December 9, 2025, Century Therapeutics announced the expansion of its Board of Directors from six to eight members, appointing Dr. Martin Murphy and Dr. Han Lee as new directors. Dr. Murphy, with extensive experience in life science investment and company creation, will serve on the Compensation and Nominating and Corporate Governance Committees, while Dr. Lee, with a strong background in capital formation and corporate development, will join the Audit and Compensation Committees. This strategic move is expected to enhance Century’s efforts to advance its iPSC-derived cell therapy programs, including its lead candidate CNTY-813 for type 1 diabetes, potentially delivering significant value to patients and stakeholders.

Century Therapeutics Launches Type 1 Diabetes Program

On November 13, 2025, Century Therapeutics announced the launch of its first program for Type 1 diabetes, CNTY-813, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND in 2026. The company is also advancing CNTY-308 through IND-enabling studies for B-cell-mediated diseases, targeting clinical study initiation in 2026. Additionally, Century reported a net loss of $34.4 million for the third quarter of 2025, with a cash runway estimated to extend into the fourth quarter of 2027, reflecting a strategic focus on high-impact therapeutic areas and resource allocation.